Market Overview

UPDATE: Morgan Stanley Reiterates On Walgreen Company As Inversion Debate Continues

Related WAG
Who Will Feel The Pain From Generic Drug Price Inflation?
Top Performing Industries For December 12, 2014
Making Money With Charles Payne: 10/22/14 (Fox Business)

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Walgreen Company (NYSE: WAG), but removed the $75.00 price target.

In the report, Morgan Stanley noted, “Political debate intensifying around high profile tax inversion deals adding to the uncertainty around the plausibility of inversion for WAG. While prospects for inversion have been a key debate for WAG shares, we see opportunities for the combined WAG/AB to lower tax rate and expand margins independent of a corporate inversion.”

Walgreen Company closed on Friday at $68.66.

Latest Ratings for WAG

DateFirmActionFromTo
Dec 2014Deutsche BankMaintainsBuy
Dec 2014CitigroupInitiates Coverage onBuy
Dec 2014Mizuho SecuritiesDowngradesBuyNeutral

View More Analyst Ratings for WAG
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (WAG)

Around the Web, We're Loving...

Get Benzinga's Newsletters